TMCNet:  Research and Markets: Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation

[July 09, 2014]

Research and Markets: Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation" report to their offering.

Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed to largely symptomatic treatments. This is currently reflected in a competitive market dominated by multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Despite this, there are significant unmet needs in the market, including afety concerns regarding immunomodulation. This is a particularly important issue for the long-term commercial and clinical success of psoriatic therapeutics, especially for emerging biologics. Another unmet need is ease of drug application, as biologic drug delivery is invasive and painful.


  • A brief introduction to psoriasis, including symptoms, pathophysiology, and overview of pharmacotherapy
  • The changing molecular target landscape between market and pipeline and particular focal points of innovation
  • Overview of how innovative products are contributing to the pipeline and market for psoriasis
  • Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of phase distribution, molecule type, molecular target, and administration route
  • Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets
  • Assessment of the licensing and co-development deals for psoriasis therapies

Key Topics Covered:

1 Table of Contents

2 The Case for Innovation

3 Clinical and Commercial Landscape

4 Assessment of Psoriasis Pipeline and Innovation

5 First-in-Class Target and Pipeline Program Evaluation

6 Deals and Strategic Consolidations

7 Appendix

For more information visit

[ Back To NFVZone's Homepage ]